Liver-Selective Acetamide Derivatives for Glucokinase Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucokinase activators often cause hypoglycemia due to excessive activation, and there is a need for compounds that can selectively activate glucokinase in the liver to treat hyperglycemia and diabetes with minimal hypoglycemic potential.
Innovation Solution
Development of a novel class of acetamide derivatives that act as liver-selective glucokinase activators, characterized by specific structural formulas and synthesis processes, which activate glucokinase to manage glucose levels without inducing excessive insulin secretion or hypoglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucokinase activators are used to lower blood glucose, then glucose-lowering effects are improved, but hypoglycemia risk increases
Solution Approach 1:
The patent applies local quality by designing compounds that selectively activate glucokinase in the liver rather than systemically throughout the body. The liver-selective activation mechanism ensures that glucose metabolism is enhanced specifically in the liver where glucokinase is abundant, avoiding excessive insulin secretion and hypoglycemia in other tissues. This spatial selectivity resolves the contradiction between effective glucose lowering and hypoglycemia prevention.
2Reliability
If glucokinase activation is enhanced to improve glucose control, then diabetes treatment efficacy is improved, but excessive insulin secretion occurs
Solution Approach 1:
The patent applies segmentation by separating the site of glucokinase activation to specifically target the liver, where glucokinase plays the primary role in glucose metabolism and glycogen storage. By segmenting the activation effect to liver-specific tissue rather than systemically activating glucokinase in all tissues including pancreatic beta cells, the invention achieves effective glucose control without triggering excessive insulin secretion that would occur with non-selective activation.
3Object-affected harmful factors
If liver-selective glucokinase activation is achieved, then hypoglycemia risk is reduced, but compound specificity requirements increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of glucokinase activators to optimize their specificity for liver glucokinase. The compounds feature specific molecular parameters including particular substituent groups (R1-R6), ring structures (rings A, B, C), and stereochemical configurations that collectively enhance binding affinity and selectivity for liver glucokinase over other hexokinase isoforms. This structural parameter optimization enables liver-selective activation while maintaining adequate therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively activate glucokinase, providing superior glucose-lowering effects with minimal risk of hypoglycemia, making them suitable for treating hyperglycemia, diabetes, obesity, and metabolic syndrome while avoiding the hypoglycemic side effects of previous activators.
Implementation Method 1
Glucokinase (GK), also known as hexokinase IV or D, is one of four glucose-phosphorylating enzymes called hexokinases that catalyze the first step of glycolysis, the conversion of glucose to glucose 6-phosphate (G6P)
Data Source
AI summary
Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed.The disclosure also provides process of preparation of these acetamide derivatives.